Survey on prescription of the new laxatives in patients with chronic constipation under daily clinical practice, using real-world data
Not Applicable
- Conditions
- chronic constipation
- Registration Number
- JPRN-UMIN000048352
- Lead Sponsor
- EA Pharma Co., Ltd. Medical Science group Medical department
- Brief Summary
ELO discontinuation (DC) rate within 360 days was 78.7%. Inpatients, end-stage renal failure, and diagnosis of constipation by obstetrics/gynecology or oncology departments were identified as risks for DC. Diagnosis of constipation, diabetes mellitus, Parkinson's disease, or use of laxative (LX) was lower risk of DC. The prescription rate of stimulants and saline LX decreased and nearly half of them discontinued these LX within 360 days. Results of M4000E were published in JPT 52(3) 253-67 in Japanese.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19295
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who have no hospital visits from 180 days to 1 day before the index date.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The following outcome will be evaluated for M4000E and ELO independently. - Drug survival of each drug after the initiation of the medication. -Risk factors for discontinuation of each drug -The prescription changes of other laxatives before and after the initiation of each drug.
- Secondary Outcome Measures
Name Time Method